Expression of NSAID-activated gene-1 by EGCG in head and neck cancer: Involvement of ATM-dependent p53 expression

Journal of Nutritional Biochemistry

Volumn 24, Issue 6, 2013, Pages 986-999

  Kang, Sung Un ^a   Lee, Bok Soon ^a   Lee, Seong Ho ^b   Baek, Seung Joon ^c   Shin, Yoo Seob ^a   Kim, Chul Ho ^a  

^a Ajou University School of Medicine   (South Korea)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Apoptosis; ATM; EGCG; Head and neck cancer; NAG 1; P53

Indexed keywords

ATM PROTEIN; CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; NONSTEROIDAL ANTIINFLAMMATORY DRUG ACTIVATED GENE 1 PROTEIN; PROTEIN; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; FEMALE; GENE; GENE ACTIVATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; MOUSE; NONHUMAN; NONSTEROIDAL ANTIINFLAMMATORY DRUG ACTIVATED GENE 1; TUMOR MODEL; TUMOR XENOGRAFT;

ANTICARCINOGENIC AGENTS; APOPTOSIS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CARCINOMA, SQUAMOUS CELL; CATECHIN; CELL LINE, TUMOR; GROWTH DIFFERENTIATION FACTOR 15; HEAD AND NECK NEOPLASMS; HETEROGRAFTS; HUMANS; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

ATAXIA TELANGIECTASIA;

EID: 84878020864     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2012.07.003     Document Type: Article

References (54)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Spitz M.R. Epidemiology and risk factors for head and neck cancer. Semin Oncol 1994, 21:281-288.
3. Sturgis E.M., Wei Q., Spitz M.R. Descriptive epidemiology and risk factors for head and neck cancer. Semin Oncol 2004, 31:726-733.
4. Surh Y. Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat Res 1999, 428:305-327.
5. Surh Y.J. Transcription factors in the cellular signaling network as prime targets of chemopreventive phytochemicals. Cancer Res Treat 2004, 36:275-286.
6. Katiyar S.K., Mukhtar H. Inhibition of phorbol ester tumor promoter 12-O-tetradecanoylphorbol-13-acetate-caused inflammatory responses in SENCAR mouse skin by black tea polyphenols. Carcinogenesis 1997, 18:1911-1916.
7. Dong Z., Huang C., Brown R.E., Ma W.Y. Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. J Biol Chem 1997, 272:9962-9970.
8. Cao Y., Cao R. Angiogenesis inhibited by drinking tea. Nature 1999, 398:381.
9. Sukhthankar M., Yamaguchi K., Lee S.H., McEntee M.F., Eling T.E., Hara Y., et al. A green tea component suppresses posttranslational expression of basic fibroblast growth factor in colorectal cancer. Gastroenterology 2008, 134:1972-1980.
10. Lamy S., Gingras D., Beliveau R. Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res 2002, 62:381-385.
11. Lim Y.C., Park H.Y., Hwang H.S., Kang S.U., Pyun J.H., Lee M.H., et al. (-)-Epigallocatechin-3-gallate (EGCG) inhibits HGF-induced invasion and metastasis in hypopharyngeal carcinoma cells. Cancer Lett 2008, 271:140-152.
12. Koh YW, Choi EC, Kang SU, Hwang HS, Lee MH, Pyun J, et al. Green tea (-)-epigallocatechin-3-gallate inhibits HGF-induced progression in oral cavity cancer through suppression of HGF/c-Met. J Nutr Biochem 2011;22:1074-83.
13. Hofmann C.S., Sonenshein G.E. Green tea polyphenol epigallocatechin-3 gallate induces apoptosis of proliferating vascular smooth muscle cells via activation of p53. FASEB J 2003, 17:702-704.
14. Naasani I., Oh-Hashi F., Oh-Hara T., Feng W.Y., Johnston J., Chan K., et al. Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo. Cancer Res 2003, 63:824-830.
15. Baek S.J., Kim K.S., Nixon J.B., Wilson L.C., Eling T.E. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001, 59:901-908.
16. Bootcov M.R., Bauskin A.R., Valenzuela S.M., Moore A.G., Bansal M., He X.Y., et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 1997, 94:11514-11519.
17. Lawton L.N., Bonaldo M.F., Jelenc P.C., Qiu L., Baumes S.A., Marcelino R.A., et al. Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta. Gene 1997, 203:17-26.
18. Paralkar V.M., Vail A.L., Grasser W.A., Brown T.A., Xu H., Vukicevic S., et al. Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. J Biol Chem 1998, 273:13760-13767.
19. Kim J.H., Chang J.H., Rhee K.H., Yoon J.H., Kwon S.H., Song K., et al. Cyclooxygenase inhibitors induce apoptosis in sinonasal cancer cells by increased expression of nonsteroidal anti-inflammatory drug-activated gene. Int J Cancer 2008, 122:1765-1773.
20. Cekanova M., Lee S.H., Donnell R.L., Sukhthankar M., Eling T.E., Fischer S.M., et al. Nonsteroidal anti-inflammatory drug-activated gene-1 expression inhibits urethane-induced pulmonary tumorigenesis in transgenic mice. Cancer Prev Res (Phila Pa). 2009, 2:450-458.
21. Thomas R., True L.D., Lange P.H., Vessella R.L. Placental bone morphogenetic protein (PLAB) gene expression in normal, pre-malignant and malignant human prostate: relation to tumor development and progression. Int J Cancer 2001, 93:47-52.
22. Iczkowski K.A., Pantazis C.G. Overexpression of NSAID-activated gene product in prostate cancer. Int J Surg Pathol 2003, 11:159-166.
23. Baek S.J., Wilson L.C., Lee C.H., Eling T.E. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 2002, 301:1126-1131.
24. Baek S.J., Wilson L.C., Eling T.E. Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 2002, 23:425-434.
25. Wilson L.C., Baek S.J., Call A., Eling T.E. Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) is induced by genistein through the expression of p53 in colorectal cancer cells. Int J Cancer 2003, 105:747-753.
26. Baek S.J., Kim J.S., Nixon J.B., DiAugustine R.P., Eling T.E. Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1. J Biol Chem 2004, 279:6883-6892.
27. Baek S.J., Kim J.S., Jackson F.R., Eling T.E., McEntee M.F., Lee S.H. Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells. Carcinogenesis 2004, 25:2425-2432.
28. Zhong Y., Krisanapun C., Lee S.H., Nualsanit T., Sams C., Peungvicha P., et al. Molecular targets of apigenin in colorectal cancer cells: involvement of p21, NAG-1 and p53. Eur J Cancer 2010, 46:3365-3374.
29. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003, 3:155-168.
30. Kurz E.U., Lees-Miller S.P. DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair (Amst) 2004, 3:889-900.
31. Fritsche M., Haessler C., Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993, 8:307-318.
32. Amin AR, Wang D, Zhang H, Peng S, Shin HJ, Brandes JC, et al. Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53. J Biol Chem 2010;285:34557-65.
33. Iguchi G., Chrysovergis K., Lee S.H., Baek S.J., Langenbach R., Eling T.E. A reciprocal relationship exists between non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) and cyclooxygenase-2. Cancer Lett 2009, 282:152-158.
34. Baek S.J., Horowitz J.M., Eling T.E. Molecular cloning and characterization of human nonsteroidal anti-inflammatory drug-activated gene promoter. Basal transcription is mediated by Sp1 and Sp3. J Biol Chem 2001, 276:33384-33392.
35. O'Malley B.W., Cope K.A., Johnson C.S., Schwartz M.R. A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg 1997, 123:20-24.
36. Zou J., Qiao X., Ye H., Yang Y., Zheng X., Zhao H., et al. Antisense inhibition of ATM gene enhances the radiosensitivity of head and neck squamous cell carcinoma in mice. J Exp Clin Cancer Res 2008, 27:56.
37. Ciardiello F., Bianco R., Damiano V., De Lorenzo S., Pepe S., De Placido S., et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999, 5:909-916.
38. Seo E.Y., Kim W.K. Red ginseng extract reduced metastasis of colon cancer cells in vitro and in vivo. J Ginseng Res 2011, 35:315-324.
39. Pisters K.M., Newman R.A., Coldman B., Shin D.M., Khuri F.R., Hong W.K., et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 2001, 19:1830-1838.
40. Shanafelt T.D., Call T.G., Zent C.S., LaPlant B., Bowen D.A., Roos M., et al. Phase I trial of daily oral polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol 2009, 27:3808-3814.
41. Tsao A.S., Liu D., Martin J., Tang X.M., Lee J.J., El-Naggar A.K., et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) 2009, 2:931-941.
42. Khan N., Afaq F., Saleem M., Ahmad N., Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 2006, 66:2500-2505.
43. Lambert J.D., Yang C.S. Mechanisms of cancer prevention by tea constituents. J Nutr 2003, 133:3262S-3267S.
44. Yang C.S., Maliakal P., Meng X. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 2002, 42:25-54.
45. Ho Y.C., Yang S.F., Peng C.Y., Chou M.Y., Chang Y.C. Epigallocatechin-3-gallate inhibits the invasion of human oral cancer cells and decreases the productions of matrix metalloproteinases and urokinase-plasminogen activator. J Oral Pathol Med 2007, 36:588-593.
46. Kato K., Long N.K., Makita H., Toida M., Yamashita T., Hatakeyama D., et al. Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral squamous cell carcinoma cells. Br J Cancer 2008, 99:647-654.
47. Tan M., Wang Y., Guan K., Sun Y. PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc Natl Acad Sci U S A 2000, 97:109-114.
48. Li P.X., Wong J., Ayed A., Ngo D., Brade A.M., Arrowsmith C., et al. Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 2000, 275:20127-20135.
49. Agarwal M.K., Hastak K., Jackson M.W., Breit S.N., Stark G.R., Agarwal M.L. Macrophage inhibitory cytokine 1 mediates a p53-dependent protective arrest in S phase in response to starvation for DNA precursors. Proc Natl Acad Sci U S A 2006, 103:16278-16283.
50. Robles A.I., Bemmels N.A., Foraker A.B., Harris C.C. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res 2001, 61:6660-6664.
51. Berger S.J., Gupta S., Belfi C.A., Gosky D.M., Mukhtar H. Green tea constituent (-)-epigallocatechin-3-gallate inhibits topoisomerase I activity in human colon carcinoma cells. Biochem Biophys Res Commun 2001, 288:101-105.
52. Bertram B., Bollow U., Rajaee-Behbahani N., Burkle A., Schmezer P. Induction of poly(ADP-ribosyl)ation and DNA damage in human peripheral lymphocytes after treatment with (-)-epigallocatechin-gallate. Mutat Res 2003, 534:77-84.
53. Lee S.H., Kim J.S., Yamaguchi K., Eling T.E., Baek S.J. Indole-3-carbinol and 3,3'-diindolylmethane induce expression of NAG-1 in a p53-independent manner. Biochem Biophys Res Commun 2005, 328:63-69.
54. Jang T.J., Kim N.I., Lee C.H. Proapoptotic activity of NAG-1 is cell type specific and not related to COX-2 expression. Apoptosis 2006, 11:1131-1138.